Phenotypes Associated with This Genotype

Genotype
MGI:4819158

• Allelic Composition: Immp2l^{Tg(HLA-A/H2-D)2Enge}/0; Tg(Mt1-RET)304Ina/0
• Genetic Background: involves: BALB/c * C57BL/6 * CBA/Ca

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:130879 )

• CD8+ T cell-depleted mice exhibit shorter survival than CD8+ T cell sufficient mice

neoplasm

increased metastatic potential ( J:130879 )

• in CD8+ T cell-depleted mice compared to in CD8+ T cell sufficient mice

increased tumor incidence ( J:130879 )

• more than 85% of mice develop tumors by 4 months of age with 50% of them exhibiting several evident cutaneous nodules at day 64

• 50% of mice without vitiligo develop visible tumors at 50 days whereas median time for tumor detection in mice with vitiligo is 88 days

increased melanoma incidence ( J:130879 )

• in 95% of mice

increased organ/body region tumor incidence ( J:130879 )

• mice develop tumors on the face earlier than in the posterior part of the body (trunk, tail, leg muscles, or genitals)

increased eye tumor incidence ( J:130879 )

• tumors first appear in the eyes

pigmentation

variable depigmentation ( J:130879 )

• 39% of mice exhibit vitiligo associated with delayed appearance of cutaneous nodules

vision/eye

increased eye tumor incidence ( J:130879 )

• tumors first appear in the eyes

exophthalmos ( J:130879 )

integument

variable depigmentation ( J:130879 )

• 39% of mice exhibit vitiligo associated with delayed appearance of cutaneous nodules

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
melanoma		DOID:1909		J:130879